A molecular stratification of chilean gastric cancer patients with potential clinical applicability

Simple item page
dc.coverageDOI: 10.3390/cancers12071863
dc.creatorPinto, Mauricio P.
dc.creatorCórdova-Delgado, Miguel
dc.creatorRetamal, Ignacio N.
dc.creatorMuñoz-Medel, Matías
dc.creatorBravo, M. Loreto
dc.creatorDurán, Doris
dc.creatorVillanueva, Francisco
dc.creatorSanchez, César
dc.creatorAcevedo, Francisco
dc.creatorMondaca, Sebastián
dc.creatorKoch, Erica
dc.creatorIbañez, Carolina
dc.creatorGalindo, Héctor
dc.creatorMadrid, Jorge
dc.creatorNervi, Bruno
dc.creatorPeña, José
dc.creatorTorres, Javiera
dc.creatorOwen, Gareth I.
dc.creatorCorvalán, Alejandro H.
dc.creatorArmisén, Ricardo
dc.creatorGarrido, Marcelo
dc.date2020
dc.date.accessioned2025-11-18T19:48:23Z
dc.date.available2025-11-18T19:48:23Z
dc.description<p>Gastric cancer (GC) is a complex and heterogeneous disease. In recent decades, The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) defined GC molecular subtypes. Unfortunately, these systems require high-cost and complex techniques and consequently their impact in the clinic has remained limited. Additionally, most of these studies are based on European, Asian, or North American GC cohorts. Herein, we report a molecular classification of Chilean GC patients into five subtypes, based on immunohistochemical (IHC) and in situ hybridization (ISH) methods. These were Epstein–Barr virus positive (EBV+), mismatch repair-deficient (MMR-D), epithelial to mesenchymal transition (EMT)-like, and accumulated (p53+) or undetected p53 (p53−). Given its lower costs this system has the potential for clinical applicability. Our results confirm relevant molecular alterations previously reported by TCGA and ACRG. We confirm EBV+ and MMR-D patients had the best prognosis and could be candidates for immunotherapy. Conversely, EMT-like displayed the poorest prognosis; our data suggest FGFR2 or KRAS could serve as potential actionable targets for these patients. Finally, we propose a low-cost step-by-step stratification system for GC patients. To the best of our knowledge, this is the first Latin American report on a molecular classification for GC. Pending further validation, this stratification system could be implemented into the routine clinic.</p>eng
dc.descriptionGastric cancer (GC) is a complex and heterogeneous disease. In recent decades, The Cancer Genome Atlas (TCGA) and the Asian Cancer Research Group (ACRG) defined GC molecular subtypes. Unfortunately, these systems require high-cost and complex techniques and consequently their impact in the clinic has remained limited. Additionally, most of these studies are based on European, Asian, or North American GC cohorts. Herein, we report a molecular classification of Chilean GC patients into five subtypes, based on immunohistochemical (IHC) and in situ hybridization (ISH) methods. These were Epstein–Barr virus positive (EBV+), mismatch repair-deficient (MMR-D), epithelial to mesenchymal transition (EMT)-like, and accumulated (p53+) or undetected p53 (p53−). Given its lower costs this system has the potential for clinical applicability. Our results confirm relevant molecular alterations previously reported by TCGA and ACRG. We confirm EBV+ and MMR-D patients had the best prognosis and could be candidates for immunotherapy. Conversely, EMT-like displayed the poorest prognosis; our data suggest FGFR2 or KRAS could serve as potential actionable targets for these patients. Finally, we propose a low-cost step-by-step stratification system for GC patients. To the best of our knowledge, this is the first Latin American report on a molecular classification for GC. Pending further validation, this stratification system could be implemented into the routine clinic.spa
dc.identifierhttps://investigadores.uandes.cl/en/publications/c3969b14-7bf3-4174-80f9-1ff5b3a40042
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/55535
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.12 (2020) nr.7 p.1-14
dc.subjectEpstein–Barr virus
dc.subjectGastric cancer
dc.subjectMolecular classification
dc.subjectMolecular subtypes
dc.subjectTargeted therapy
dc.subjectEpstein–Barr virus
dc.subjectGastric cancer
dc.subjectMolecular classification
dc.subjectMolecular subtypes
dc.subjectTargeted therapy
dc.subjectSDG 3 - Good Health and Well-being
dc.titleA molecular stratification of chilean gastric cancer patients with potential clinical applicabilityeng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
PURE